The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

Yildirim, Hasan Cagri; Kutlu, Yasin; Mutlu, Emel; Aykan, Musa Baris; Korkmaz, Mustafa; Yalcin, Selim; Sakalar, Teoman; Celayir, Ozde Melisa; Kayikcioglu, Erkan; Aslan, Ferit; Hafizoglu, Emre; Altintas, Yunus Emre; Keskinkilic, Merve; Chalabiyev, Elvin; Celebi, Abdussamet; Dursun, Bengu; Kapar, Caner; Ozen, Mirac; Acar, Oemer; Dulgar, Ozgecan; Kut, Engin; Biter, Sedat; Kus, Fatih; Almuradova, Elvina; Erdogan, Atike Pinar; Saray, Seray; Guven, Deniz Can; Simsek, Eda Tanrikulu; Uskent, Necdet; Kemal, Yasemin; Cakar, Burcu; Acikgoz, Ozgur; Kilickap, Saadettin; Aksoy, Sercan

doi:10.1007/s10147-023-02460-5

The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

Date

2024

Authors

Yildirim, Hasan Cagri

dc.identifier.doi

10.1007/s10147-023-02460-5

dc.identifier.other

WOS:001156854500001

Publisher

SPRINGER JAPAN KK

DOI

10.1007/s10147-023-02460-5

Keywords

Male breast cancer , CDK4 , 6 inhibitors , Palbociclib , Ribociclib

URI

https://openaccess.acibadem.edu.tr/handle/11443/5935

Collections

WOS

Full item page

The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

Date

Authors

Journal Title

Journal ISSN

Volume Title

dc.identifier.issn

dc.identifier.doi

dc.identifier.other

dc.description.volume

dc.description.issue

Publisher

DOI

Abstract

Description

Keywords

Citation

URI

Collections

Endorsement

Review

Supplemented By

Referenced By